Huseyin Avni Solgun

Huseyin Avni Solgun

Auto-generated profile, based on publicly available information

Huseyin Avni Solgun

Saglik Bilimleri Universitesi

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2023 in Thrombosis Journal
Verified
Journal Article
Open access
PDF file
HSHuseyin Avni Solgun
Huseyin Avni Solgun
EUEzgi Paslı Uysalol
Ezgi Paslı Uysalol
CBCengiz Bayram
Cengiz Bayram
ÖTÖzlem Terzi
Özlem Terzi
MÇMerih Çetinkaya
Merih Çetinkaya
AAAli Aycicek
Ali Aycicek
Background: Neonatal portal vein thrombosis (PVT) is currently more commonly encountered as a result of advances in diagnostic tools and increase in invasive interventions. Methods: In this study, 11 premature and 12 term infants diagnosed with PVT were retrospectively evaluated for clinical and laboratory characteristics, umbilical catheterization procedure, PVT location, risk factors, treatments, and long-term outcomes. Results: Median age of the patients at diagnosis was 10 days (range 3–90 days), and 69.6% of patients were girls. Of the 23 patients, 87% had left PVT and, 91.3% had at least one thrombosis risk factor, which was sepsis in 73.9% of patients, and presence of umbilical venous catheter in 87%. Totally, 59.1% of PVTs were completely resolved in a median follow-up of 7 months (1 month to 12 months), and 78.3% of these patients had no anticoagulant therapy (ACT). Partial thrombus resolution was achieved in 9 patients (40.9%). Five patients (%21) received ACT. Overall, 34.8% of patients had long-term complications. neonatal PVT is most commonly reported in the left portal vein and there is no evidence for the impact of ACT on reducing the short- or long-term complications. Well designed and larger studies are necessary to clarify this issue, which can facilitate developing appropriate management algorithms. Conclusion: Neonatal PVT is most commonly reported in the left portal vein and there is no evidence for the impact of ACT on reducing the short- or long-term complications. Well designed and larger studies are necessary to clarify this issue, which can facilitate developing appropriate management algorithms.

1 March 2011 in Tuberk Toraks
Verified
Journal Article
Closed access
HSHuseyin Avni Solğun
Huseyin Avni Solğun
<%=header_description %> <%=header_description %>

5 January 2025 in Italian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
HSHüseyin Avni Solgun
Hüseyin Avni Solgun
Background: Rare bleeding disorders (RBDs) include fibrinogen (Factor I), prothrombin (Factor II), Factor V(FV), combined Factor V and Factor VIII, Factor VII, Factor X, Factor XI, Factor XII, and Factor XIII deficiencies. This group accounts for 3–5% of all factor deficiencies. Different symptoms may occur, ranging from mild or moderate bleeding to serious and life-threatening bleeding, which may not be related to the factor level. This study aimed to evaluate the diagnosis, genetics, treatment, prophylaxis features and surgical experiences of patients those are followed up in our clinic and the review of the literature of rare factor deficiency. Methods: Demographic data, number of follow-up visits throughout the study period, clinical symptoms, number and locations of bleeding symptoms of 19 patients diagnosed with RBD (fibrinogen, prothrombin, FV, FVII, FX, FXI or FXIII) who were followed up in our pediatric hematology clinic between year 2023–2024 and complications, inhibitor levels, previous operations, treatment and prophylaxis approaches are recorded in the patient chart and all data had been evaluated retrospectively. In our article, all patients included in this study are mentioned according to the consecutive numbering system as Patient 1(P1) to P19 in Table 2. A comprehensive literature search was performed in PubMed and after primary elections 4 studies are selected from total 23 studies those are most relevant to RBDs in pediatric age as there is only plenty of articles about RBDs. Most of the other studies are reviews without clinical patient trails just including recommadations for diagnosis and laboratuary screenings. In contrast, our study includes a clinical trail on diagnosis, treatment and prophylaxis information of 19 patients with RBDs. Results: The average age of total 19 patients was 11.2 years (range 2,5–17 years). 14 patients were boys (74%) and 5 patients were girls (26%). 10 of the patients (52%) had FVII deficiency (mean FVII: 8,3%, range 2,5–17%), 4 of patients (21%) had FX deficiency (mean FX:16,2%, range 15–17%) and 4 of patients (21%) had FV deficiency (mean FV:14%, range 10–17%) and 1 had FXIII deficiency (1%) respectively. The normal range laboratory reference values for rare blood factor levels in our institute (factor V, VII and X deficencies) is 70–120%. In our study group, 63% (12/19) of our patients were diagnosed over one year of age. Considering all of our cases, skin and soft tissue bleedings are listed as 52% (10/19), intraoral bleedings as 42% (8/19), nose bleedings as 63% (12/19), joint bleedings as 42%(8/19) and santral nerveous system(CNS) bleedings as 15%(3/19). Among the serious bleedings of our cases, joint bleeding 42% (8/19) takes the first place with followed by CNS bleeding 15% (3/19) and gastro-intestinal system(GIS) bleeding (15%) (3/19) respectively. Among totally 19 patients, FX deficiency-P17 had a null mutation of FX gene and FV deficiency-P3 had a missense mutation of FV gene has been detected those both were severe deficencies. The medical genetics of the sibling patients with combined FVII deficency and hypofibrinogenemia have been evaluated, but the genetic results have not been completed yet. Conclusions: We believe that data-based service is required in every clinic and healthcare system for early diagnosis and follow-up of RBDs. Additionially family screenings and more effective genetic counseling may heal the overall survival and prevent further severe complications. Moreover; the missing factor, severity of deficiency, personal and family history of bleeding or thrombosis, availability of treatment options, plasma half-life of infused exogenous clotting factors and infusion frequency, advantages and disadvantages should all be considered before a prophylaxis program or treatment of RBDs.

11 July 2019 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
PDF file
HSHuseyin Avni Solgun
Huseyin Avni Solgun
TPTugcin Bora Polat
Tugcin Bora Polat
In many cases of total anomalous pulmonary venous connection (TAPVC), the four pulmonary veins (PV) join together behind the left atrium, where they form a collector. This collector can drain into the right atrium directly through the innominate vein into the superior vena cava (SVC), into the coronary sinus (CS), or through the diaphragm to the venous structures of the abdomen. In our case, a mature newborn had TAPVC draining into the vena porta along with severe pulmonary hypertension. Additionally, there were right pulmonary sequestration, dextrocardia, transposition of the great arteries, severe pulmonary stenosis, and single ventricular pathology in echocardiographic examination. Clinical signs manifested in the first 7 days of life. Diagnostic tools used were echocardiography and angiography. A ductal stent was surgically implanted into the ductus arteriosus by angiography. TAPVC was found to be nonobstructive. Therefore, we would like to emphasize the rareness and hardness to perform the surgical ductal implant technique in our particular case of TAPVC with pulmonary sequestration draining into the vena porta. The prognosis in TAPVC is poor and related mainly to the existence of pulmonary venous obstruction.

1 January 2022 in Turkish Archives of Pediatrics
Verified
Journal Article
Open access
HSHüseyin Avni Solgun
Hüseyin Avni Solgun
EAEsra Aslantaş
Esra Aslantaş
GÖGül Nihal Özdemir
Gül Nihal Özdemir
Cite this article as: Solgun HA, Aslantaş E, Özdemir GN. Management of venous thrombosis in a T-cell acute lymphoblastic leukemia case with superior Vena Cava syndrome. Turk Arch Pediatr. 2022;57(1):108-110.

1 March 2020 in Cardiovascular Pathology
Verified
Journal Article
Closed access
FGFarid Gojayev
Farid Gojayev
HSHuseyin Avni Solgun
Huseyin Avni Solgun
KAKoray Ak
Koray Ak
AMAhmet Midi
Ahmet Midi
YCYasemin Canillioglu
Yasemin Canillioglu